• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login

    • Esophageal Cancer Companies

    ID: MRFR/Pharma/2380-HCR
    110 Pages
    Kinjoll Dey
    September 2025

    Esophageal cancer is a type of malignancy that affects the esophagus, the tube that connects the throat to the stomach. Various companies are actively involved in the development of diagnostic tools, treatments, and therapeutic interventions for esophageal cancer.

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Esophageal Cancer Market Research Report- Forecast To 2034 Infographic
    Summary Table of Contents Segmentation Infographic

    Top Industry Leaders in the Esophageal Cancer Market

    Esophageal Cancer Key Companies

     

    Latest Esophageal Cancer Companies Update


    Dec 2023Henlius Biotech (China) Received NMPA approval for HANSIZHUANG (serplulimab), an anti-PD-1 monoclonal antibody, in combination with fluorouracil and platinum for first-line treatment of PD-L1 positive unresectable locally advanced, recurrent or metastatic ESCC.Partnered with leading cancer centers in China and other regions to conduct clinical trials for their pipeline of esophageal cancer drugs.


    AstraZeneca (UK) Received FDA Breakthrough Therapy Designation for Imfinzi® (durvalumab) in combination with chemotherapy for unresectable locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) after first-line therapy.Launched awareness campaigns and educational initiatives to improve early diagnosis and access to treatment for esophageal cancer.


    Boehringer Ingelheim (Germany) Presented positive Phase 2 data for their novel JNK/TGF-beta-targeted therapy BIB104 in patients with advanced esophageal cancer, paving the way for further clinical development.Collaborated with academic institutions and clinical research organizations to explore innovative treatment approaches for esophageal cancer.


    Johnson & Johnson (US) Announced positive Phase 3 results for their PD-1 inhibitor Tremfya® (guselkumab) in combination with chemotherapy for locally advanced or metastatic esophageal cancer, suggesting potential for improved survival rates.Invested in research and development of next-generation immunotherapy drugs with tailored target specificity for enhancing efficacy and reducing side effects.


    Esai (Japan) Developed a new AI-powered system for analyzing endoscopic images to assist in early detection of esophageal cancer and improve diagnostic accuracy.Partnered with technology companies to develop advanced diagnostic tools and personalized treatment platforms for esophageal cancer patients.


    List of Esophageal Cancer Key Companies in the Market



    • Amgen

    • Eli Lilly and Company

    • Hoffmann-La Roche

    • Bristol-Myers Squibb Company

    • Boehringer Ingelheim GmbH

    • Bristol-Myers Squibb

    • GlaxoSmithKline Plc.

    • Novartis AG

    • Johnson & Johnson

    • Gilead Sciences

    • Merck & Co.